Skip Navigation

JNCI Journal of the National Cancer Institute 1995 87(6):427-436; doi:10.1093/jnci/87.6.427
© 1995 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Apple, R. J.
Right arrow Articles by Erlich, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Apple, R. J.
Right arrow Articles by Erlich, H. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 87, No. 6, 427-436, March 15, 1995
© 1995 Oxford University Press

Comparison of Human Leukocyte Antigen DR-DQ Disease Associations Found With Cervical Dysplasia and Invasive Cervical Carcinoma

Raymond J. Apple, Thomas M. Becker, Cosette M. Wheeler, Henry A. Erlich

Roche Molecular Systems, Department of Human Genetics Alameda, Calif
Epidemiology and Cancer Control Program, University of New Mexico Cancer Research and Treatment Center Albuquerque, N.M
Department of Cell Biology and Epidemiology and Cancer Control Program,, University of New Mexico Cancer Research and Treatment Center Albuquerque, N.M

Correspondence to: Cosette M. Wheeler, Ph.D., Department of Cell Biology, University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM 87131.

Background: Human leukocyte antigen (HLA) molecules, whose biological role is in the regulation of immune responses to foreign antigens and in discrimination of self from non-self antigens, are encoded by a series of closely linked genetic loci found on chromosome 6. Although the evidence for a link between HLA and cervical cancer has been controversial, it has been recently reported that certain HLA class II haplotypes (linked class II alleles) are positively associated with invasive cervical cancer, while other class II haplotypes are negatively associated or protective. Since HLA associations between human papillomavirus type 16 (HPV16)-mediated cancer cases and non-HPV16-mediated cancer cases have been found to be different, this suggests that specific HLA class II haplotypes may influence the immune response to HPV infection and may affect the risk of acquiring invasive cervical carcinoma. Purpose: This study was conducted to determine if the same HLA class II haplotypes that are associated with invasive cervical carcinoma are also associated with cervical dysplasia (pre-sumed precursors of invasive cervical cancer). Methods: We have examined HLA DR-DQ haplotypes among 128 Hispanic women from New Mexico with biopsy-confirmed cervical dysplasia in a case-control study using sensitive DNA-based polymerase chain reaction amplification and sequence-specific oligonucleotide probe hybridization methods to detect the presence and type of HPV and to detect allelic polymorphism in the HLA DRB1 and DQB1 loci. Results: Dysplasia cases were divided into two groups for comparison to controls: severe dysplasia/carcinoma in situ (CIS), and slight/moderate dysplasia. The frequency distribution of HLA class II haplotypes among the HPV16-positive severe dysplasia/CIS cases had a statistically significant (two-tailed P<.005) difference compared with controls, whereas haplotypes among the severe dysplasia/CIS cases containing HPV types other than HPV16 did not show statistically significant frequency differences. DR-DQ haplotypes previously found to be associated with HPV16-invasive cervical carcinomas were also associated with HPV16-positive severe dysplasia/CIS. However, no statistically significant haplotype frequency difference was observed between slight/moderate dysplasia cases and controls. In addition, we noted a DQA1-DQB1 haplotype negatively associated with severe dysplasia/CIS but not with invasive cervical cancers. Conclusions: Our results strongly suggest that certain HLA haplotypes confer an increased risk for severe cervical dysplasia and invasive cervical carcinoma following HPV16 infection. Implications: Further molecular studies are needed to identify HLA alleles or haplotypes that may provide increased susceptibility to HPV-associated cervical disease. [J Natl Cancer Inst 87: 427–436, 1995]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. Butsch Kovacic, M. Martin, X. Gao, T. Fuksenko, C.-J. Chen, Y.-J. Cheng, J.-Y. Chen, R. Apple, A. Hildesheim, and M. Carrington
Variation of the Killer Cell Immunoglobulin-Like Receptors and HLA-C Genes in Nasopharyngeal Carcinoma
Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2673 - 2677.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Friborg, J. Wohlfahrt, A. Koch, H. Storm, O. R. Olsen, and M. Melbye
Cancer Susceptibility in Nasopharyngeal Carcinoma Families--A Population-Based Cohort Study
Cancer Res., September 15, 2005; 65(18): 8567 - 8572.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
M Zoodsma, I M Nolte, M Schipper, E Oosterom, G van der Steege, E G E de Vries, G J te Meerman, and A G J van der Zee
Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study
J. Med. Genet., August 1, 2005; 42(8): e49 - e49.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. I. O. Garner
Cervical Cancer: Disparities in Screening, Treatment, and Survival
Cancer Epidemiol. Biomarkers Prev., March 1, 2003; 12(3): 242s - 247s.
[Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
E. M. Burd
Human Papillomavirus and Cervical Cancer
Clin. Microbiol. Rev., January 1, 2003; 16(1): 1 - 17.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. E. Strome, A. Savva, A. E. Brissett, B. S. Gostout, J. Lewis, A. C. Clayton, R. McGovern, A. L. Weaver, D. Persing, and J. L. Kasperbauer
Squamous Cell Carcinoma of the Tonsils: A Molecular Analysis of HPV Associations
Clin. Cancer Res., April 1, 2002; 8(4): 1093 - 1100.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
K. Bordenave, J. Griffith, S. M. Hordes, T. M. Williams, and R. S. Padilla
The Historical and Geomedical Immunogenetics of Pemphigus Among the Descendants of Sephardic Jews in New Mexico
Arch Dermatol, June 1, 2001; 137(6): 825 - 826.
[Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
N. D. Christensen, R. Han, N. M. Cladel, and M. D. Pickel
Combination Treatment with Intralesional Cidofovir and Viral-DNA Vaccination Cures Large Cottontail Rabbit Papillomavirus-Induced Papillomas and Reduces Recurrences
Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1201 - 1209.
[Abstract] [Full Text]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. C. Maciag, N. F. Schlecht, P. S. A. Souza, E. L. Franco, L. L. Villa, and M. L. Petzl-Erler
Major Histocompatibility Complex Class II Polymorphisms and Risk of Cervical Cancer and Human Papillomavirus Infection in Brazilian Women
Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1183 - 1191.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Chaudhuri, A. Cariappa, M. Tang, D. Bell, D. A. Haber, K. J. Isselbacher, D. Finkelstein, D. Forcione, and S. Pillai
Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles
PNAS, October 10, 2000; 97(21): 11451 - 11454.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.